Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Onconetix (ONCO) EBITDA (2023 - 2025)

Onconetix (ONCO) has disclosed EBITDA for 2 consecutive years, with -$33.2 million as the latest value for Q4 2024.

  • On a quarterly basis, EBITDA fell 66.12% to -$33.2 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$63.8 million, a 82.12% decrease, with the full-year FY2024 number at -$63.8 million, down 82.12% from a year prior.
  • EBITDA was -$33.2 million for Q4 2024 at Onconetix, down from -$435896.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$435896.0 in Q3 2024 to a low of -$33.2 million in Q4 2024.